Endo International PLC

Endo International — UBS Global Healthcare Conference 2015

20 slides from Endo International's conference presentation, May 20, 2015

  1. Slide 1: Endo at UBS Global Healthcare Conference, May 20, 2015

    Slide 1: Endo at UBS Global Healthcare Conference, May 20, 2015

    Exhibit 99.1 Exhibit Endo UBS May ©2015 20, Healthcare International Endo 99.1 2015Pharmaceuticals Conference plc Inc. All rights reserved.

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward This Section of possible “will,” forward-looking expressed conditions regulatory successful Endo’s Exchange and aevents 1©complete 2015 the annual presentation transaction, occur “may” Endo control; 21E or Looking Commission in authorities as to discussion reports assumed of the in Pharmaceu

  3. Slide 3: Non-GAAP Financial Measures

    Slide 3: Non-GAAP Financial Measures

    2at Non-GAAP prepared related (benefit) milestones; non-GAAP because between provided efforts. Additional meaningful. This with charge ©2015 presentation theat to This itSEC current, for in athe www.sec.gov Endo cost enhances quantitative Information financial conformity stock-based Financial is inc

  4. Slide 4: Par Acquisition: Compelling Strategic Rationale

    Slide 4: Par Acquisition: Compelling Strategic Rationale

    3©2015 Par Compelling Strategically capabilities Adds Focus Designed Double-digit synergies, Drives and Strong in Aligned creating Creates 12-18 Pharmaceutical size, extensive on strategic R&D cash shareholder growth with months establishing specialized, Endoto increased and flow Strategic accelerat

  5. Slide 5: Par Acquisition Overview

    Slide 5: Par Acquisition Overview

    Endo $1.55 $6.5 Fully Includes Creates 2014 Par 1Expected 4©Source: 2015 Pharmaceutical CEO billion pro to committed billion Endo leading acquire assumption forma Paul to IMScash be close in Pharmaceuticals Campanelli Health financed equity specialty revenues privately-held consideration financing i

  6. Slide 6: About Par Pharmaceutical

    Slide 6: About Par Pharmaceutical

    About Founded Headquarters: Manufacturing 2,000 Privately-held as Generics Multiple products, Branded Revenue 5© 2015 twoemployees Par business Endo :dosage of CAGR in :Paragraph 2approx. Pharmaceutical 1978 $1.3 approved, Pharmaceuticals Woodcliff pharmaceutical Facilities: segments: forms of billi

  7. Slide 7: Par Revenue, Adjusted Gross Margin and Pipeline Evolution

    Slide 7: Par Revenue, Adjusted Gross Margin and Pipeline Evolution

    Par Revenue Adj. #Filed $1,050 2012 6$1,309 75% 35% 9% 25% 2014 ofPharmaceutical: ANDAs Technologies Gross Market 47% 52% ($mm) Profit 85 115 on opportunity $21bn File $37bn Margin Evolution 814($bn)from 2012 to Today

  8. Slide 8: Endo + Par Creates a Top 5 U.S. Generics Player

    Slide 8: Endo + Par Creates a Top 5 U.S. Generics Player

    Endo U.S. ($ GEP [2] $0 $5 7ce:inIMS IMS [3] billions) + Par: Health Generics Creates $10 LTM Sales aas Top of 510/31/14, GenericsWall Player Street research. ro forma for acquisition of Par [2] Pro forma for acquisition of Ranbaxy [3] Pro form for acquisition of Hospira

  9. Slide 9: Endo + Par: Attractive Specialty Pharma Landscape

    Slide 9: Endo + Par: Attractive Specialty Pharma Landscape

    Endo Spec ($ $167 Attractive Expanding Generics $100 Source: $6 $8 $9 $12 $20 $33 $44 $54 8$62 in billions) Pharma $103 $75 + Par: FactSet. business $50 Branded international ALandscape $25 Leading Note: now $0 portfolio Market focused Specialty profile by Enterprise &data R&D onPharmaceutical high

  10. Slide 10: Par Acquisition: Growth and Value Creation

    Slide 10: Par Acquisition: Growth and Value Creation

    Par Growth Capabilities Diversifies Multiple Synergies Accretion Expands Revenue: EPS: Accretive with ~20% Operational Strategically Transaction Anticipate Enables 9© 2015 Acquisition: mid expect accretion Endo Profile de-levering manufacturing teens double-digit toreturns product multiple and adjus

  11. Slide 11: Endo + Par: Double-Digit Adjusted Diluted EPS Growth

    Slide 11: Endo + Par: Double-Digit Adjusted Diluted EPS Growth

    Endodouble-digit Adjusted 2015 2016 Low Contribution: 10 -> + Par: 2016 2017 Diluted Driving midEPS ~20% growth teens accretion Double-Digit %for accretion, base business Growth depending to on timing of transaction close

  12. Slide 12: Par Acquisition: Projected Opportunities and Value-Driven Transaction

    Slide 12: Par Acquisition: Projected Opportunities and Value-Driven Transaction

    Par Acquisition: Projected Opportunities Estimated Adjusted Transaction 11x 10x $732 $805 $120 $150 $200 $480 $520 $20 $30 $50 $70 $5 $15 $434 2014A Existing 2015E 2016E Synergies Pipeline 11 Products EBITDA increase show EBITDA multiple presented net A in Value-Driven ($mm) of only on Par expected

  13. Slide 13: Par: Future Anticipated Product Launches

    Slide 13: Par: Future Anticipated Product Launches

    Par: Future Anticipated Launch 2015 Date($mm) Jun Late July Has Nov Dec *Par 12Partnered pipeline 2015 TA Anticipated 2016 2016 2015 Dexmethylphenidate Earnings on Par Fluvastatin Ezetimibe Rosuvastatin Quetiapine Rivastigmine all Product Program Approx. contains 5 strengths; Visibility Product Bran

  14. Slide 14: Par Acquisition: Prudent Financial Structure and Deleveraging

    Slide 14: Par Acquisition: Prudent Financial Structure and Deleveraging

    Par Double-digit Adjusted Robust Prudent Net 5.0x Transaction ~3x ~3.5x ~4x ~4.5x ~5x *w/AMS Assumes 13Represents Deal Leverage 4.0x cash financial Proceeds Structure EBITDA $2B 3.0x Close flow pro Net Ratio* Equity 2.0x forma Debt structure conversion Transaction Enables margin 1.0x Raise /adjusted

  15. Slide 15: Endo Summary: Transformative Size and Scale

    Slide 15: Endo Summary: Transformative Size and Scale

    Endo Summary: Size Company Generics Long ~$20bn ~$2.9bn ~$1.1bn 6~90 Expansion 2014 ~$1.3bn 215 Strong Enterprise ~$28bn Pro ~$4.2bn ~300 ~$2.4bn Top Transformative ©2015 Appendix 14 ANDAs forma programs five and Revenue: development Term +performance Endo Par: (+56% (+19% in Scale (2014) R&D to 201

  16. Slide 16: Appendix

    Slide 16: Appendix

    ©2015 Endo Pharmaceuticals Inc. All rights reserved. Appendix

  17. Slide 17: Reconciliation of Net Loss to Adjusted EBITDA, Fiscal 2014

    Slide 17: Reconciliation of Net Loss to Adjusted EBITDA, Fiscal 2014

    Reconciliation Fiscal December 2014 (Successor) (unaudited) ($ Statement Net Interest Provision (Benefit) Depreciation EBITDA Litigation AWP. Restructuring Transaction Upfront Inventory Intangible Cost Loss Gain Stock Run-rate Management Special Other(p) Adjusted (a) “inventory (b) claims remaining

  18. Slide 18: Reconciliation Footnotes

    Slide 18: Reconciliation Footnotes

    Reconciliation (h) acquired approximately originally recorded products partially discounted (i) 520.3 efficacy addition, rights (j) Actavis gains (k) deferred amended were (I) ANDAs FAS6 gain (m) (n) force. previously Zuplenz* (o) advisory this consulting to (p) 17 December In During During In Other

  19. Slide 19: Reconciliation of Par Non-GAAP Gross Margin

    Slide 19: Reconciliation of Par Non-GAAP Gross Margin

    2011the Reconciliation For July January Fiscal December 2013 2014 September 2010 12, years Period 1, 2012 31, 2012 28 ended to 2012 oftoPar December, December Non-GAAP 31, Measures—Gross Margin (unaudited) {unaudited) (Predecessor) {Successor) (Successor) [Successor) $Gross $366,744 $342,353 Amortiz

  20. Slide 20: Endo at UBS Global Healthcare Conference, May 20, 2015

    Slide 20: Endo at UBS Global Healthcare Conference, May 20, 2015

    Endo20, UBS May ©2015 Healthcare International Endo 2015Pharmaceuticals Conference plc Inc. All rights reserved.

Source: SEC EDGAR · 8-K filed May 20, 2015

More decks from Endo International PLC